• Profile
Close

Metformin use associates with longer progression-free survival of patients with diabetes and pancreatic neuroendocrine tumors receiving everolimus and/or somatostatin analogues

Gastroenterology Apr 22, 2018

Pusceddu S, et al. - The tie-up between glycemia and progression-free survival (PFS) of patients with neuroendocrine tumors (NETs) treated with everolimus and/or somatostatin analogues was comprehensively analyzed by researchers. They also gauged the correlation between metformin use and PFS time at 24 medical centers in Italy, from 1999 through 2015. It was deduced that PFS of patients treated with metformin was considerably longer than for patients without diabetes and longer than for patients with diabetes receiving other treatments. Therefore, a prominent link was brought to light between metformin use and longer PFS.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay